Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire

Front Immunol. 2021 May 19:12:672737. doi: 10.3389/fimmu.2021.672737. eCollection 2021.

Abstract

Abacavir hypersensitivity syndrome can occur in individuals expressing the HLA-B*57:01 major histocompatibility complex class I allotype when utilising the drug abacavir as a part of their anti-retroviral regimen. The drug is known to bind within the HLA-B*57:01 antigen binding cleft, leading to the selection of novel self-peptide ligands, thus provoking life-threatening immune responses. However, the sub-cellular location of abacavir binding and the mechanics of altered peptide selection are not well understood. Here, we probed the impact of abacavir on the assembly of HLA-B*57:01 peptide complexes. We show that whilst abacavir had minimal impact on the maturation or average stability of HLA-B*57:01 molecules, abacavir was able to differentially enhance the formation, selectively decrease the dissociation, and alter tapasin loading dependency of certain HLA-B*57:01-peptide complexes. Our data reveals a spectrum of abacavir mediated effects on the immunopeptidome which reconciles the heterogeneous functional T cell data reported in the literature.

Keywords: MHC I antigen presentation; T cells; abacavir; drug hypersensitivity; immunopeptidome; peptide selection; tapasin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / immunology*
  • Cell Line
  • Dideoxynucleosides / adverse effects
  • Dideoxynucleosides / immunology*
  • Drug Hypersensitivity / immunology*
  • HLA-B Antigens / immunology*
  • HLA-B Antigens / metabolism
  • Humans
  • Kinetics
  • Lymphocyte Activation / immunology
  • T-Lymphocytes / immunology*

Substances

  • Anti-HIV Agents
  • Dideoxynucleosides
  • HLA-B Antigens
  • HLA-B*57:01 antigen
  • abacavir